Clinical Trial Update: Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) [Phase 2]

View source ↗

Summary

Phase 2 trial update on repeated intravenous thrombolysis with tenecteplase for ischemic stroke within 3 hours of onset; currently enrolling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Tenecteplase (tenecteplase)

Snippet

Sponsor: General Hospital of Shenyang Military Region | Conditions: Ischemic Stroke | Phase 2 | Status: RECRUITING